Barriers and facilitators for family physicians prescribing opioid agonist therapy in Saskatchewan

被引:0
|
作者
Nguyen, Teresa [1 ]
Bareham, Julia [2 ]
Halpape, Katelyn [3 ]
机构
[1] Loblaw Pharm Saskatoon, Saskatoon, SK, Canada
[2] Univ Saskatchewan, RxFiles Acad Detailing Program, Saskatoon, SK, Canada
[3] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK, Canada
关键词
COLLABORATIVE CARE; BUPRENORPHINE; EXPERIENCE; ABSTINENCE; ADDICTION; METHADONE;
D O I
10.46747/cfp.7004e52
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To explore barriers and facilitators for family physicians in Saskatchewan prescribing opioid agonist therapy (OAT). Design Self-administered postal survey. Setting Family medicine practices in Saskatchewan. Participants A total of 218 Saskatchewan family physicians who were not authorized to prescribe OAT as of June 2022. Main outcome measures Descriptive and inferential statistics of physicians' self-reported barriers to and facilitators of prescribing OAT for opioid use disorder (OUD). Results Most respondents (84.8%) had some comfort with diagnosing OUD. However, more than half (58.3%) did not feel confident or knowledgeable about prescribing OAT. Barriers to OAT prescribing included lack of time, incomplete training requirements, lack of interest, insufficient funding or support, feeling overwhelmed, and perceiving that OAT does not work and thus is not necessary. Physicians working in core neighbourhoods and those receiving fee-for-service compensation reported the least available time to prescribe OAT. Conversely, physicians working in interdisciplinary team settings had increased time for OAT prescribing compared with physicians in other settings. Having a close personal relationship with someone with OUD was correlated with increased comfort in diagnosing OUD as well as with knowledge about and confidence in prescribing OAT. Themes identified as facilitators to increasing OAT prescribing included the addition of resources and supports, increased training, more awareness about OUD and OAT, enhanced compensation, and altered prescribing regulations. Conclusion Despite the presence of several real and perceived barriers limiting OAT prescribing by Saskatchewan family physicians, there are family physicians interested in providing this therapy. Increased clinical resources and support, including increased interdisciplinary practice, are actionable steps that should be considered by policy decision makers to address this issue. Additionally, increased OUD and OAT education, which includes the perspectives of those with lived experience of OUD, would help address physician confidence, knowledge, and awareness in this area.
引用
收藏
页码:e52 / e60
页数:9
相关论文
共 50 条
  • [21] Opioid Prescribing in Rural Family Practices: A Qualitative Study
    Click, Ivy A.
    Basden, Jeri Ann
    Bohannon, Joy M.
    Anderson, Heather
    Tudiver, Fred
    SUBSTANCE USE & MISUSE, 2018, 53 (04) : 533 - 540
  • [22] Considerations when prescribing opioid agonist therapies for people living with HIV
    Tarfa, Adati
    Lier, Audun J.
    Shenoi, Sheela V.
    Springer, Sandra A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2024, 17 (07) : 549 - 564
  • [23] A social ecological model (SEM) to exploring barriers of and facilitators to the implementation of opioid agonist treatment (OAT) programmes in prisons
    Komalasari, Rita
    Wilson, Sarah
    Haw, Sally
    INTERNATIONAL JOURNAL OF PRISONER HEALTH, 2021, 17 (04) : 477 - 496
  • [24] Survey of barriers and opportunities for prescribing buprenorphine for opioid use disorder in Alabama
    Patel, Ishika
    Li, Li
    Jeong, Haelim
    Mcdaniel, Justin T.
    Mcintosh, Shanna
    Robertson, Ellen
    Albright, David L.
    JOURNAL OF ADDICTIVE DISEASES, 2024, 42 (04) : 410 - 417
  • [25] Changing patterns of opioid agonist therapy prescribing in a network of specialised clinics providing care to people with opioid use disorder in Victoria, Australia, 2015 to 2023
    Dawe, Joshua
    Wilkinson, Anna Lee
    Curtis, Michael
    Asselin, Jason
    Henderson, Charles
    Makoni, Eric
    Dietze, Paul
    Hellard, Margaret
    Stoove, Mark
    DRUG AND ALCOHOL REVIEW, 2025,
  • [26] Individual Factors Associated with Opioid Agonist Therapy Retention in Northern Ontario
    Oukachbi, Salima
    Rizzo, Saara
    CANADIAN JOURNAL OF ADDICTION, 2020, 11 (01) : 19 - 29
  • [27] Practice Predictors of Buprenorphine Prescribing by Family Physicians
    Peterson, Lars E.
    Morgan, Zachary J.
    Borders, Tyrone F.
    JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE, 2020, 33 (01) : 118 - 123
  • [28] Barriers to Opioid Substitution Treatment Access, Entry and Retention: A Survey of Opioid Users, Patients in Treatment, and Treating and Non-Treating Physicians
    Stoever, Heino
    EUROPEAN ADDICTION RESEARCH, 2011, 17 (01) : 44 - 54
  • [29] Barriers and facilitators to opioid agonist treatment (OAT) engagement among individuals released from federal incarceration into the community in Ontario, Canada
    Russell, Cayley
    Pang, Michelle
    Nafeh, Frishta
    Farrell Macdonald, Shanna
    Derkzen, Dena
    Rehm, Jurgen
    Fischer, Benedikt
    INTERNATIONAL JOURNAL OF QUALITATIVE STUDIES ON HEALTH AND WELL-BEING, 2022, 17 (01)
  • [30] Facilitators and Barriers to Family Involvement in Problem Gambling Treatment
    Kourgiantakis, Toula
    Saint-Jacques, Marie-Christine
    Tremblay, Joel
    INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION, 2018, 16 (02) : 291 - 312